参考文献/References:

[1] 周自强, 胡大一, 陈捷, 等．中国心房颤动现状流行病学研究 [J] .中华内科杂志, 2004, 43(7):491

[2] Feinberg W M, Blackshear J L, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation [J]. Arch Intern Med, 1995,155(5):469

[3] Go A S, Hylek E M, Phillips K A, et al. Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the Anticoagulation and Risk Factors in Atrial Fibril- lation ( ATRIA ) Study [J].JAMA, 2001,285(18):2370

[4] Miyasaka Y, Barnes M E, Gersh B J, et al. Secular trends in incidence of atrial fibrillation in Olmsted County,Minnesota,1980 to 2000,and implications on the projections for future prevalence [J]. Circulation, 2006,114(2):119

[5] 艾克拜尔·安尼瓦尔, 李俊红, 木拉提·阿不都热合曼.心房颤动治疗的研究新进展[J].中国循环杂志,2014,11:955

[6] 邹彤,杨杰孚.心房颤动的抗心律失常药物治疗现状[J].中国心血管杂志, 2008,13(2):147

[7] 谢艳美.心可舒联合乙胺碘呋酮治疗冠心病快速心房纤颤45例[J].陕西医学杂志，2012,41(12):1609

[8] 刘孟娟,周陈西. 205例胺碘酮不良反应文献分析[J]. 中国临床药学杂志, 2011,(1):47

[9] Flaker G, Lopes R D, Hylek E, et al. Amiodarone,anticoagulation,and clinical events in patients with atrial fibrillation:insights from the ARISTOTLE trial[J].J Am coll Cardiol, 2014,64 (15):1541

[10] 唐源,王国干,宋有城.伊布利特---一种新的类抗心律失常药[J].心血管病学进展,2000,21(2):78

[11] Fedida D, Orth P M, Chen J Y, et al. The mechanism of atrial anti- arrhythmic action of RSD1235[J]. J Cardiovasc Electro- physiol,2005,16(11):1227

[12] Patel C, Salahuddin M, Jones A, et al.Atrial fibrillation: pharmaco- logical therapy[J].Curr Probl Cardiol,2011,36(3):87

[13] 张海澄, 郭继鸿, 方全, 等. 静脉注射伊布利特与普罗帕酮转复心房颤动和扑动的多中心研究[J]. 中华医学杂志,2005,12:798

[14] Simon A, Niederdoeckl J, Skyllouriotis E, et al.Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department[J]. Europace, 2016,3(22):052

[15] 李琼,曾学寨,封宇飞. Ⅲ类抗心律失常新药多非利特[J].中国药学杂志, 2004,39(8):568

[16] Abraham J M, Saliba W I, Vekstein C, et al.Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter[J]. Circ Arrhythm Electrophysiol,2015,8(4):772

[17] Agusala K, Oesterle A, Kulkarni C, et al.Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation[J]. Pacing Clin Electrophysiol ， 2015，38(4):490

[18]Lalevée N，Barrère-Lemaire S，Gautier P, et al.Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardio- myocytes[J]. J Cardiovasc Electro- physiol， 2003, 14(8):885

[19] Gautier P, Guillemare E, Marion A, et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells[J]. J Cardiovasc Pharmacol,2003,41(2):191

[20] Varró A, Takács J, Németh M,et al.Electrophysiological effects of dronedarone (SR 33589),a noniodinated amiodarone derivative in the canine heart:comparison with amiodarone[J].Br J Pharmacol, 2001,133(5):625

[21] Hancox J C. Amiodarone blocks L-type calcium current in single myocytes isolated from the rabbit atrioventricular node[J]. Gen Pharmacol, 1997,29(3):429

[22] Thomas D, Kathofer S, et al. Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels[J].Br J Pharmacol,2003, 140(5):996

[23] Ridley J M, Milnes J T, Witchel H J, et al. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone:resistance to mutations of the S6 residues Y652 and F656[J].Biochem Biophys Res Commun,2004,325(3):883

[24] Bosch R F, Li G R, Gaspo R,et al. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes[J].J Pharm Exp Ther,1999, 289(1):156

[25] Aimond F, Beck L, Gautier P, et al. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats[J]. J Pharmacol Exp Ther, 2000,292(1):415

[26] Guillemare E, Marion A, Nisato D, et al. Inhibitory effects of dronedarone on muscarinic K current in guinea pig atrial cells[J]. J Cardiovasc Pharmacol, 2001,36(6):802

[27] Altomare C,Barbuti A,Viscomi C,et al. Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells[J]. Br J Pharmacol,2000,130(6):1315

[28] Chatelain P, Meysmans L, Mattéazzi J R, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β‐adrenoceptor and adenylate cyclase in rat heart[J].Br J Pharmacol, 1995,116(3):1949

[29] Sardar M R, Saeed W, Kowey P R. Antiarrhythmic drug therapy for atrial fibrillation[J]. Cardiology Clinics,2014,32(4):533

[30] Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation:a dose-ranging study[J].Eur Heart J, 2004,13(1):1481

[31] Jean-Marc D, Martin H, Christer H, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study[J].Am Heart J,2008,156(3): 527

[32] Patel C 1, Yan G X, Kowey P R. Dronedarone[J].Circulation,2009,120

(7):636

[33] Connolly S J, Jonathan L, Halper I N, et al.Dronedarone in high-risk permanent atrial fibrillation[J].N Engl J Med, 2011, 365(24):2268

[34] Kǒber L, Torp-Pedersen C, McMurray J J, et al.Increased mortality after dronedarone therapy for severe heart failure[J].N Engl J Med, 2008, 358(25):2678

[35] Wettwer E, Christ T, Endig S, et al.The new antiarrhythmic drug vernakalant:ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation[J].Cardiovas Res ,2013, 98(1): 145

[36] Stiell IG, Roos J S, Kavanagh K M, et al.A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm[J].Am Heart J,2010,159(6):1095

[37] Camm A J, Capucci A, Hohnloser S H, et al.A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation[J].J Am Coll Cardiol,2011,57(3):313

[38] Scirica B M, Belardinelli L, Chaitman B R, et al.Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes:observations from the MERLIN-TIMI 36 trial[J]. Europace, 2015, 17(1):32

[39] Fragakis N, Koskinas K C, Katritsis D G, et al.Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation[J].Am J Cardiol,2012,110(5):673

[40] Tardif J C.Clinical efficacy of Ivabradine[J].Heart Drug,2005, 5 (1):25

[41] Herrmann S, Layh B, Ludwig A. Novel insights into the distribution of cardiac HCN channels:an expression study in the mouse heart[J].J Mol Cell Cardiol,2011,51(51):997

[42] Verrier R L, Sobrado M F, Pagotto V P, et al. Inhibition of I_(f) in the atrioventricular node as a mechanism for dronedarone’s reduction in ventricular rate during atrial fibrillation[J].Heart Rhythm, 2013, 10 (11):1692

[43] Verrier R L, Silva A F, Bonatti R, et al.Combined actions of Ivabradine and ranolazine reduce ventricular rate during atrial fibrillation[J]. J Card Electrophysiol,2015,26(3):329

相似文献/References:

[1]王爱芬,崔利军,马向红.非瓣膜性心房颤动左心房/左心耳血栓形成的相关因素分析[J].天津医科大学学报,2015,21(02):130.
　WANG Ai-fen,CUI Li-jun,MA Xiang-hong.Related factors of left atrial or left atrial appendage thrombus formation in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(01):130.
[2]陈延勋,李广平. 非瓣膜性心房颤动患者尿酸与ＣＨＡＤＳ2、CHA２ＤＳ２－ＶＡＳｃ评分的关系[J].天津医科大学学报,2015,21(03):185.
　CHEN Yan-xun,LI Guang-ping. Relationship between uric acid and CHADS2/CHA2DS2-VASc Score in patients with nonvalvular atrial fibrillation[J].Journal of Tianjin Medical University,2015,21(01):185.
[3]崔占前,徐延敏.脂蛋白相关性磷脂酶A2及高敏C反应蛋白与左心房内径的关系[J].天津医科大学学报,2015,21(03):196.
　CUI Zhan-qian,XU Yan-min.Relationship between plasma lipoprotein-associated phospholipase A2, high sensitivity C reactive protein and left atrial diameter[J].Journal of Tianjin Medical University,2015,21(01):196.
[4]付伟伟,李国东,王喆.HDL-C与非瓣膜性心房颤动左心房/左心耳血栓形成的关系[J].天津医科大学学报,2015,21(06):498.
　FU Wei-wei,LI Guo-dong,WANG Zhe.Relationship between high-density lipoprotein cholesterol and left atrial / left atrial appendage thrombus in non-valvular atrial fibrillation patients[J].Journal of Tianjin Medical University,2015,21(01):498.
[5]张彦月,林文华.vWF及血浆D-二聚体水平对非瓣膜性心房颤动患者血栓形成的诊断及临床预后价值[J].天津医科大学学报,2016,22(02):101.
　ZHANG Yan-yue,LIN Wen-hua.Value of vWF and?D-dimer for thrombosis and prognosis in patients with non-valvular atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(01):101.
[6]刘运龄,赵艳淑,刘恩照,等.不同类型心房颤动患者心脏结构及B型钠尿肽水平的变化[J].天津医科大学学报,2016,22(06):522.
　LIU Yun-ling,ZHAO Yan-shu,LIU En-zhao,et al.Relationship between plasma leves B-type natriuretic peptide and cardiac structure in patients with different types of atrial fibrillation[J].Journal of Tianjin Medical University,2016,22(01):522.
[7]张凤环,上官文锋,王学文,等.血管紧张素-（1-7）对快速心房起搏犬心房重构及p38MAPK蛋白表达的影响[J].天津医科大学学报,2019,25(05):450.
　ZHANG Feng-huan,SHANGGUAN Wen-feng,WANG Xue-wen,et al.Effect of angiotensin-(1-7) on atrial remodeling and p38MAPK expression in a canine model of rapid atrial pacing[J].Journal of Tianjin Medical University,2019,25(01):450.
[8]杜春蕾,郭牧,张云强,等.尼非卡兰和胺碘酮治疗急性心肌梗死新发房颤有效性和安全性对比研究[J].天津医科大学学报,2019,25(05):471.
　DU Chun-lei,GUO Mu,ZHANG Yun-qiang,et al.Comparison of nifekalant and amiodarone in the treatment of new-onset atrial fibrillation in acute myocardial infarction patients[J].Journal of Tianjin Medical University,2019,25(01):471.
[9]张茂芃,陈炳伟,卢成志,等.脉冲场消融治疗心房颤动的短期及长期安全性临床研究[J].天津医科大学学报,2023,29(06):636.
　ZHANG Mao-peng,CHEN Bing-wei,LU Cheng-zhi,et al.The short-term and long-term safety clinical trial of pulse field ablation to treat atrial fibrillation[J].Journal of Tianjin Medical University,2023,29(01):636.

[1]张邦滢综述,李广平审校.新型抗心律失常药物在心房颤动中的应用[J].天津医科大学学报,2017,23(01):90-封3.

点击复制

新型抗心律失常药物在心房颤动中的应用(PDF)

分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

文章信息/Info

参考文献/References:

[12] Patel C, Salahuddin M, Jones A, et al.Atrial fibrillation: pharmaco- logical therapy[J].Curr Probl Cardiol,2011,36(3):87

[14] Simon A, Niederdoeckl J, Skyllouriotis E, et al.Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department[J]. Europace, 2016,3(22):052

[17] Agusala K, Oesterle A, Kulkarni C, et al.Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation[J]. Pacing Clin Electrophysiol ， 2015，38(4):490

[24] Bosch R F, Li G R, Gaspo R,et al. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes[J].J Pharm Exp Ther,1999, 289(1):156

[28] Chatelain P, Meysmans L, Mattéazzi J R, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β‐adrenoceptor and adenylate cyclase in rat heart[J].Br J Pharmacol, 1995,116(3):1949

[29] Sardar M R, Saeed W, Kowey P R. Antiarrhythmic drug therapy for atrial fibrillation[J]. Cardiology Clinics,2014,32(4):533

[33] Connolly S J, Jonathan L, Halper I N, et al.Dronedarone in high-risk permanent atrial fibrillation[J].N Engl J Med, 2011, 365(24):2268

[34] Kǒber L, Torp-Pedersen C, McMurray J J, et al.Increased mortality after dronedarone therapy for severe heart failure[J].N Engl J Med, 2008, 358(25):2678

[35] Wettwer E, Christ T, Endig S, et al.The new antiarrhythmic drug vernakalant:ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation[J].Cardiovas Res ,2013, 98(1): 145

[36] Stiell IG, Roos J S, Kavanagh K M, et al.A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm[J].Am Heart J,2010,159(6):1095

[37] Camm A J, Capucci A, Hohnloser S H, et al.A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation[J].J Am Coll Cardiol,2011,57(3):313

[38] Scirica B M, Belardinelli L, Chaitman B R, et al.Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes:observations from the MERLIN-TIMI 36 trial[J]. Europace, 2015, 17(1):32

[39] Fragakis N, Koskinas K C, Katritsis D G, et al.Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation[J].Am J Cardiol,2012,110(5):673

[40] Tardif J C.Clinical efficacy of Ivabradine[J].Heart Drug,2005, 5 (1):25

[43] Verrier R L, Silva A F, Bonatti R, et al.Combined actions of Ivabradine and ranolazine reduce ventricular rate during atrial fibrillation[J]. J Card Electrophysiol,2015,26(3):329

相似文献/References:

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics

[1]张邦滢 综述,李广平 审校.新型抗心律失常药物在心房颤动中的应用[J].天津医科大学学报,2017,23(01):90-封3. 点击复制 新型抗心律失常药物在心房颤动中的应用(PDF) 分享到： var jiathis_config = { data_track_clickback: true };

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

文章信息/Info

参考文献/References:

[12] Patel C, Salahuddin M, Jones A, et al.Atrial fibrillation: pharmaco- logical therapy[J].Curr Probl Cardiol,2011,36(3):87

[14] Simon A, Niederdoeckl J, Skyllouriotis E, et al.Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department[J]. Europace, 2016,3(22):052

[17] Agusala K, Oesterle A, Kulkarni C, et al.Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation[J]. Pacing Clin Electrophysiol ， 2015，38(4):490

[24] Bosch R F, Li G R, Gaspo R,et al. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes[J].J Pharm Exp Ther,1999, 289(1):156

[28] Chatelain P, Meysmans L, Mattéazzi J R, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β‐adrenoceptor and adenylate cyclase in rat heart[J].Br J Pharmacol, 1995,116(3):1949

[29] Sardar M R, Saeed W, Kowey P R. Antiarrhythmic drug therapy for atrial fibrillation[J]. Cardiology Clinics,2014,32(4):533

[33] Connolly S J, Jonathan L, Halper I N, et al.Dronedarone in high-risk permanent atrial fibrillation[J].N Engl J Med, 2011, 365(24):2268

[34] Kǒber L, Torp-Pedersen C, McMurray J J, et al.Increased mortality after dronedarone therapy for severe heart failure[J].N Engl J Med, 2008, 358(25):2678

[35] Wettwer E, Christ T, Endig S, et al.The new antiarrhythmic drug vernakalant:ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation[J].Cardiovas Res ,2013, 98(1): 145

[36] Stiell IG, Roos J S, Kavanagh K M, et al.A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm[J].Am Heart J,2010,159(6):1095

[37] Camm A J, Capucci A, Hohnloser S H, et al.A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation[J].J Am Coll Cardiol,2011,57(3):313

[38] Scirica B M, Belardinelli L, Chaitman B R, et al.Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes:observations from the MERLIN-TIMI 36 trial[J]. Europace, 2015, 17(1):32

[39] Fragakis N, Koskinas K C, Katritsis D G, et al.Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation[J].Am J Cardiol,2012,110(5):673

[40] Tardif J C.Clinical efficacy of Ivabradine[J].Heart Drug,2005, 5 (1):25

[43] Verrier R L, Silva A F, Bonatti R, et al.Combined actions of Ivabradine and ranolazine reduce ventricular rate during atrial fibrillation[J]. J Card Electrophysiol,2015,26(3):329

相似文献/References:

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics

[1]张邦滢综述,李广平审校.新型抗心律失常药物在心房颤动中的应用[J].天津医科大学学报,2017,23(01):90-封3.

点击复制

新型抗心律失常药物在心房颤动中的应用(PDF)

分享到：